content_image/935677.jpg content_image/935678.jpg
such compounds can be significantly reduced and, in some cases, may even be eliminated. 

In one aspect, methods for preparing a pharmaceutical composition are featured, which include: 

(i) providing a first combination that includes: 

(a) one (or more) peptide proteasome inhibitors (e.g., a compound of formula (1)-(5) or a pharmaceutically acceptable salt thereof); 

(b) one or more cyclodextrins ("CDs"); and 

( c) water; 

wherein the first combination is heterogeneous and the compound or salt has a low solubility in the first combination; and 

(ii) contacting the first combination with an acid to form a second combination, wherein the compound is more soluble in the second combination than in the first combi- nation. 

In another aspect, methods for preparing a pharmaceutical composition are featured, which include: 

(i) providing a first combination that includes: 

(a) a compound: 

<img src='content_image/935677.jpg'>

or a pharmaceutically acceptable salt thereof; 

(b) one or more cyclodextrins ("CDs"); and 

(c) water; 

wherein the first combination is heterogeneous and the compound or salt has a low solubility in the first combination; and 

(ii) contacting the first combination with an acid to form a second combination, wherein the compound is more soluble in the second combination than in the first combi- nation. 

In a further aspect, methods for preparing a pharmaceu- tical composition are featured, which include: 

(i) providing a first combination that includes: 

(a) a compound: 

<img src='content_image/935678.jpg'>

or a pharmaceutically acceptable salt thereof; 

(b) SBECD; and 

(c) water for injection; 

wherein the first combination is heterogeneous and the compound or salt has a low solubility in the first combination; and 

(ii) contacting the first combination with an aqueous solution of citric acid to form a second combination, wherein the compound is more soluble in the second combination than in the first combination. 

In one aspect, pharmaceutical compositions are featured, which are prepared by any one of the methods described herein. 

In one aspect, methods for treating cancer (e.g., multiple myeloma, e.g., multiple myeloma that is relapsed and/or refractory) in a patient are featured, which include admin› istering to the patient a therapeutically effective amount of a pharmaceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating autoimmune dis› ease in a patient are featured, which include administering to the patient a therapeutically effective amount of a pharma› ceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating graft or transplant- related condition in a patient are featured, which include administering to the patient a therapeutically effective amount of a pharmaceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating neurodegenerative disease in a patient are featured, which include administer› ing to the patient a therapeutically effective amount of a pharmaceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating fibrotic-associated condition in a patient are featured, which include adminis› tering to the patient a therapeutically effective amount of a pharmaceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating fibrotic-associated condition in a patient are featured, which include adminis› tering to the patient a therapeutically effective amount of a pharmaceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating ischemic-related condition in a patient are featured, which include adminis› tering to the patient a therapeutically effective amount of a pharmaceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating an infection in a patient are featured, which include administering to the patient a therapeutically effective amount of a pharmaceu› tical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating an infection in a patient are featured, which include administering to the patient a therapeutically effective amount of a pharmaceu› tical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating disease associated with bone loss in a patient are featured, which include administering to the patient a therapeutically effective amount of a pharmaceutical composition prepared by any one of the methods described herein. 

In another aspect, methods for treating an infection in a patient are featured, which include administering to the patient a therapeutically effective amount of a pharmaceu› tical composition prepared by any one of the methods described herein. 

Embodiments can include one or more of the following features. 

The first combination does not include appreciable amounts of any organic solvent(s). In some embodiments, 

